Heat Biologics Inc (HTBX) 5.83 $HTBX
Nasdaq stocks posting largest percentage increases
AP - Thu Feb 12, 12:20PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
HTBX: 5.83 (+0.22), ADXS: 7.18 (+0.06), CYAN: 8.72 (+0.13), STMP: 56.92 (-0.24), EPRS: 7.67 (+0.67), EEFT: 53.96 (-0.91), PRQR: 18.32 (-0.86), GTIM: 8.23 (+0.07), DPRX: 12.76 (+0.26), EXPE: 89.49 (-0.08), CVV: 14.68 (-0.26), DGLY: 11.50 (-0.40), DWSN: 6.89 (-0.42)
Heat Biologics Presents Positive Preclinical Data on a Novel Approach to Combination Immunotherapy at the Keystone Symposia on Tumor Immunology
GlobeNewswire - Wed Feb 11, 9:55AM CST
Heat Biologics, Inc. (Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, announced today the presentation of data demonstrating the incorporation of T-cell costimulatory fusion proteins into Heat's gp96-Ig vaccine platform, at a Keystone Symposia on "Tumor Immunology -- Multidisciplinary Science Driving Combination Therapy," which is being held in Banff, Canada. The study is part of ongoing development work at Heat to introduce a novel combination immunotherapy product simultaneously expressing its gp96-Ig vaccine and individual T-cell costimulatory fusion proteins.
HTBX: 5.83 (+0.22)
Heat Bio up 15% on positive preclinical data
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 8:28AM CST
HTBX: 5.83 (+0.22)
Heat Biologics, Inc. to Present at the BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 9:05AM CST
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, today announced that Jeff Wolf, CEO, will present a corporate update at the BIO CEO & Investor Conference, being held at the Waldorf-Astoria Hotel in New York City February 9-10, 2015.
HTBX: 5.83 (+0.22)
Heat Biologics, Inc. Outlines 2015 Corporate Objectives
GlobeNewswire - Mon Feb 02, 7:00AM CST
- Significant Clinical Progress Anticipated with Two Lead Immunotherapy Programs -
HTBX: 5.83 (+0.22)
Nasdaq stocks posting largest volume increases
AP - Tue Jan 27, 5:09PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
BLVD: 9.73 (+0.04), HTBX: 5.83 (+0.22), GLBZ: 12.65 (+0.35), LSCC: 6.10 (+0.02), SAL: 28.70 (unch), CRDS: 2.32 (+0.05), WVFC: 11.02 (-0.45), CRRC: 22.96 (+0.22), AMRB: 9.59 (-0.06), NFEC: 2.11 (+0.02), STAA: 6.76 (-0.02), SIMG: 7.25 (-0.01), SBSI: 29.39 (-0.01), UPI: 1.27 (unch), RITT: 1.29 (unch)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 26, 11:46AM CST
HTBX: 5.83 (+0.22), NES: 3.52 (+0.13), TEAR: 2.15 (+0.03), FENG: 7.92 (+0.23), OCN: 9.10 (+0.09), STX: 61.83 (+0.67), LACO: 8.38 (+0.17), PHMD: 1.68 (+0.04), BBEP: 7.85 (+0.32), HGSH: 3.05 (-0.13), MBT: 10.36 (+0.62), NBG: 1.61 (+0.18), NDRM: 10.76 (+0.22), PT: 0.83 (+0.04), POST: 48.62 (-0.25), ATNM: 3.60 (-0.29), MWV: 53.91 (+0.59), WRES: 1.27 (+0.01), IDN: 1.43 (-0.01), KONE: 4.20 (+0.03)
Heat Biologics presents positive Phase 1 data on HS-410
Seeking Alpha - at Seeking Alpha - Mon Jan 26, 9:47AM CST
HTBX: 5.83 (+0.22)
Heat Biologics, Inc. Presents Positive Immunological Data on HS-410 in Non-Muscle Invasive Bladder Cancer at the 7th Annual Phacilitate Immunotherapy Forum 2015
GlobeNewswire - Mon Jan 26, 7:00AM CST
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, today announced positive data demonstrating substantially increased tumor infiltrating lymphocytes following treatment in its Phase 1 clinical trial of HS-410 in non-muscle invasive bladder cancer (NMIBC). The data are being presented today by Taylor Schreiber, MD, PhD, the Company's Vice President of Research and Development, during the 7 Annual Phacilitate Immunotherapy Forum 2015, held in Washington, D.C.
HTBX: 5.83 (+0.22)
Heat Biologics, Inc. to Present at the 7th Annual Phacilitate Immunotherapy Forum 2015
GlobeNewswire - Fri Jan 23, 7:32AM CST
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, today announced that Taylor Schreiber, MD, PhD, Vice President of Research and Development, and Eckhard Podack, MD, PhD, Scientific Founder, will be speaking at the 7 Annual Phacilitate Immunotherapy Forum 2015, being held at the Grand Hyatt Hotel in Washington, D.C. from January 26-28, 2015.
HTBX: 5.83 (+0.22)
Heat Biologics, Inc. to Present at the Noble Financial Capital Markets Equity Conference
GlobeNewswire - Thu Jan 15, 7:59AM CST
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, today announced that Jeff Wolf, CEO, will present a corporate update at the Noble Financial Capital Markets Equity Conference, being held at Club Med in Sandpiper Bay, Florida on Monday, January 19, 2015 at 9:30am Eastern Time. Taylor Schrieber will also be participating in their Immunotherapy panel on January 19 at 5:00pm.
HTBX: 5.83 (+0.22)
New Chairman and CEO Take the Helm at Z Trim
ACCESSWIRE - Wed Jan 14, 3:16PM CST
MUNDELEIN, IL / ACCESSWIRE / January 14, 2015 / Z Trim Holdings, Inc. ("ZTH" (OTC Markets: ZTHO), an AgriTech company providing value-added ingredients to a variety of industries, today announced that it has appointed veteran Directors Ed Smith and Morris Garfinkle as CEO and Chairman of the Board, respectively, effective January 8, 2015. Outgoing CEO Steve Cohen will become Managing Director of Communication and Planning.
HTBX: 5.83 (+0.22)
Heat Biologics, Inc. Expands Product Development Team to Support Development of Lead Product Candidates in Oncology
GlobeNewswire - Tue Dec 02, 7:00AM CST
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, today announced the expansion of its product development team. Three new director-level team members have joined Heat to help execute its Phase 2 strategy and prepare for Phase 3 delivery. The new hires will assume responsibility for Manufacturing, Regulatory Affairs and Quality Assurance, and Clinical Operations under the direction of Dr. Melissa Price, VP of Clinical and Regulatory Affairs.
HTBX: 5.83 (+0.22)
Heat Biologics, Inc. to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2 in New York
GlobeNewswire - Mon Dec 01, 7:01AM CST
Heat Biologics, Inc. ("Heat" (Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, today announced that Jeff Wolf, CEO, will present a corporate update at the 26 Annual Piper Jaffray Healthcare Conference, taking place at the New York Palace Hotel, December 2-3, 2014.
HTBX: 5.83 (+0.22)
Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST
HTBX: 5.83 (+0.22), BIB: 141.30 (+2.39), INCY: 75.94 (+0.28), PFE: 34.64 (-0.23), IBB: 323.46 (+3.04), DRGS: 56.69 (unch), BIND: 6.06 (+0.21), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), ONTY: 1.57 (unch), ECYT: 5.26 (-0.02), BIS: 39.67 (-0.75), CLVS: 68.79 (+0.71), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), ARIA: 7.35 (+0.45), IRY: 49.63 (+0.34), IXJ: 104.21 (+0.61), FPRX: 24.63 (+0.63)
Heat Biologics Q3 results
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 9:07AM CST
HTBX: 5.83 (+0.22)
Nasdaq stocks posting largest percentage increases
AP - Thu Feb 12, 12:20PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
HTBX: 5.83 (+0.22), ADXS: 7.18 (+0.06), CYAN: 8.72 (+0.13), STMP: 56.92 (-0.24), EPRS: 7.67 (+0.67), EEFT: 53.96 (-0.91), PRQR: 18.32 (-0.86), GTIM: 8.23 (+0.07), DPRX: 12.76 (+0.26), EXPE: 89.49 (-0.08), CVV: 14.68 (-0.26), DGLY: 11.50 (-0.40), DWSN: 6.89 (-0.42)
Heat Biologics Presents Positive Preclinical Data on a Novel Approach to Combination Immunotherapy at the Keystone Symposia on Tumor Immunology
GlobeNewswire - Wed Feb 11, 9:55AM CST
Heat Biologics, Inc. (Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, announced today the presentation of data demonstrating the incorporation of T-cell costimulatory fusion proteins into Heat's gp96-Ig vaccine platform, at a Keystone Symposia on "Tumor Immunology -- Multidisciplinary Science Driving Combination Therapy," which is being held in Banff, Canada. The study is part of ongoing development work at Heat to introduce a novel combination immunotherapy product simultaneously expressing its gp96-Ig vaccine and individual T-cell costimulatory fusion proteins.
HTBX: 5.83 (+0.22)
Heat Bio up 15% on positive preclinical data
Seeking Alpha - at Seeking Alpha - Wed Feb 11, 8:28AM CST
HTBX: 5.83 (+0.22)
Heat Biologics, Inc. to Present at the BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 9:05AM CST
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, today announced that Jeff Wolf, CEO, will present a corporate update at the BIO CEO & Investor Conference, being held at the Waldorf-Astoria Hotel in New York City February 9-10, 2015. HTBX: 5.83 (+0.22)
Heat Biologics, Inc. Outlines 2015 Corporate Objectives
GlobeNewswire - Mon Feb 02, 7:00AM CST
- Significant Clinical Progress Anticipated with Two Lead Immunotherapy Programs -
HTBX: 5.83 (+0.22)
Nasdaq stocks posting largest volume increases
AP - Tue Jan 27, 5:09PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
BLVD: 9.73 (+0.04), HTBX: 5.83 (+0.22), GLBZ: 12.65 (+0.35), LSCC: 6.10 (+0.02), SAL: 28.70 (unch), CRDS: 2.32 (+0.05), WVFC: 11.02 (-0.45), CRRC: 22.96 (+0.22), AMRB: 9.59 (-0.06), NFEC: 2.11 (+0.02), STAA: 6.76 (-0.02), SIMG: 7.25 (-0.01), SBSI: 29.39 (-0.01), UPI: 1.27 (unch), RITT: 1.29 (unch)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Jan 26, 11:46AM CST
HTBX: 5.83 (+0.22), NES: 3.52 (+0.13), TEAR: 2.15 (+0.03), FENG: 7.92 (+0.23), OCN: 9.10 (+0.09), STX: 61.83 (+0.67), LACO: 8.38 (+0.17), PHMD: 1.68 (+0.04), BBEP: 7.85 (+0.32), HGSH: 3.05 (-0.13), MBT: 10.36 (+0.62), NBG: 1.61 (+0.18), NDRM: 10.76 (+0.22), PT: 0.83 (+0.04), POST: 48.62 (-0.25), ATNM: 3.60 (-0.29), MWV: 53.91 (+0.59), WRES: 1.27 (+0.01), IDN: 1.43 (-0.01), KONE: 4.20 (+0.03)
Heat Biologics presents positive Phase 1 data on HS-410
Seeking Alpha - at Seeking Alpha - Mon Jan 26, 9:47AM CST
HTBX: 5.83 (+0.22)
Heat Biologics, Inc. Presents Positive Immunological Data on HS-410 in Non-Muscle Invasive Bladder Cancer at the 7th Annual Phacilitate Immunotherapy Forum 2015
GlobeNewswire - Mon Jan 26, 7:00AM CST
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, today announced positive data demonstrating substantially increased tumor infiltrating lymphocytes following treatment in its Phase 1 clinical trial of HS-410 in non-muscle invasive bladder cancer (NMIBC). The data are being presented today by Taylor Schreiber, MD, PhD, the Company's Vice President of Research and Development, during the 7 Annual Phacilitate Immunotherapy Forum 2015, held in Washington, D.C. HTBX: 5.83 (+0.22)
Heat Biologics, Inc. to Present at the 7th Annual Phacilitate Immunotherapy Forum 2015
GlobeNewswire - Fri Jan 23, 7:32AM CST
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, today announced that Taylor Schreiber, MD, PhD, Vice President of Research and Development, and Eckhard Podack, MD, PhD, Scientific Founder, will be speaking at the 7 Annual Phacilitate Immunotherapy Forum 2015, being held at the Grand Hyatt Hotel in Washington, D.C. from January 26-28, 2015. HTBX: 5.83 (+0.22)
Heat Biologics, Inc. to Present at the Noble Financial Capital Markets Equity Conference
GlobeNewswire - Thu Jan 15, 7:59AM CST
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, today announced that Jeff Wolf, CEO, will present a corporate update at the Noble Financial Capital Markets Equity Conference, being held at Club Med in Sandpiper Bay, Florida on Monday, January 19, 2015 at 9:30am Eastern Time. Taylor Schrieber will also be participating in their Immunotherapy panel on January 19 at 5:00pm. HTBX: 5.83 (+0.22)
New Chairman and CEO Take the Helm at Z Trim
ACCESSWIRE - Wed Jan 14, 3:16PM CST
MUNDELEIN, IL / ACCESSWIRE / January 14, 2015 / Z Trim Holdings, Inc. ("ZTH"
(OTC Markets: ZTHO), an AgriTech company providing value-added ingredients to a variety of industries, today announced that it has appointed veteran Directors Ed Smith and Morris Garfinkle as CEO and Chairman of the Board, respectively, effective January 8, 2015. Outgoing CEO Steve Cohen will become Managing Director of Communication and Planning. HTBX: 5.83 (+0.22)
Heat Biologics, Inc. Expands Product Development Team to Support Development of Lead Product Candidates in Oncology
GlobeNewswire - Tue Dec 02, 7:00AM CST
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, today announced the expansion of its product development team. Three new director-level team members have joined Heat to help execute its Phase 2 strategy and prepare for Phase 3 delivery. The new hires will assume responsibility for Manufacturing, Regulatory Affairs and Quality Assurance, and Clinical Operations under the direction of Dr. Melissa Price, VP of Clinical and Regulatory Affairs. HTBX: 5.83 (+0.22)
Heat Biologics, Inc. to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2 in New York
GlobeNewswire - Mon Dec 01, 7:01AM CST
Heat Biologics, Inc. ("Heat"
(Nasdaq:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, today announced that Jeff Wolf, CEO, will present a corporate update at the 26 Annual Piper Jaffray Healthcare Conference, taking place at the New York Palace Hotel, December 2-3, 2014. HTBX: 5.83 (+0.22)
Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST
HTBX: 5.83 (+0.22), BIB: 141.30 (+2.39), INCY: 75.94 (+0.28), PFE: 34.64 (-0.23), IBB: 323.46 (+3.04), DRGS: 56.69 (unch), BIND: 6.06 (+0.21), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), ONTY: 1.57 (unch), ECYT: 5.26 (-0.02), BIS: 39.67 (-0.75), CLVS: 68.79 (+0.71), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), ARIA: 7.35 (+0.45), IRY: 49.63 (+0.34), IXJ: 104.21 (+0.61), FPRX: 24.63 (+0.63)
Heat Biologics Q3 results
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 9:07AM CST
HTBX: 5.83 (+0.22)
